Lite Strategy (LITS) Other financing activities (2011 - 2022)
Lite Strategy (LITS) posted Other financing activities of $360000.0 for Q1 2022, up 437.31% on a QoQ basis from $67000.0 in Q2 2021, and up 185.71% year-over-year from $126000.0 in Q1 2021.
Analysis
Lite Strategy (LITS) Other financing activities (2011 - 2022) Analysis & Trends
Lite Strategy has reported Other financing activities for 7 years, with the latest figure at $360000.0 in Q1 2022.
- On a quarterly basis, Other financing activities rose 185.71% year-over-year to $360000.0 in Q1 2022; TTM through Jun 2023 was $360000.0, a 34.9% decrease from a year earlier, with the FY2024 full-year figure at $208000.0, changed N/A from the prior year.
- Other financing activities was $360000.0 for Q1 2022 at Lite Strategy, up from $67000.0 in the prior quarter.
- The five-year high for Other financing activities was $70.0 million in Q2 2018, with the low at $15000.0 in Q4 2020.
- Average Other financing activities over 5 years is $9.6 million, with a median of $243000.0 recorded in 2021.
- The sharpest annual moves came in 2018 and 2020: Other financing activities soared 5490.0% in 2018, then plunged 97.65% in 2020.
- Over 5 years, Other financing activities stood at $1.1 million in 2018, then surged by 371.74% to $5.3 million in 2019, then slumped by 99.72% to $15000.0 in 2020, then jumped by 346.67% to $67000.0 in 2021, then soared by 437.31% to $360000.0 in 2022.
- The last three Other financing activities figures came in at $360000.0 (Q1 2022), $67000.0 (Q2 2021), and $126000.0 (Q1 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2022 | 360,000.00 |
| Jun 30, 2021 | 67,000.00 |
| Mar 31, 2021 | 126,000.00 |
| Dec 31, 2020 | 15,000.00 |
| Sep 30, 2020 | 124,000.00 |
| Sep 30, 2019 | 5.27 Mn |
| Sep 30, 2018 | 1.12 Mn |
| Jun 30, 2018 | 69.96 Mn |
| Dec 31, 2017 | 169,000.00 |
| Sep 30, 2017 | 20,000.00 |
| Dec 31, 2011 | 365,000.00 |
| Sep 30, 2011 | 397,000.00 |